Low-dosage sublingual aspirin

• US 4,866,046 A
• Filed: 05/31/1988
• Issued: 09/12/1989
• Est. Priority Date: 05/31/1988
• Status: Expired due to Term

• Current Assignee: Moh. Samir Amer
• Original Assignee: Top Laboratories, Inc.
• Inventors: Amer, Moh. S.
• Primary Examiner(s): Friedman, Stanley J.
• Application Number:
  US07/199,679
• Time in Patent Office: 469 Days
• Field of Search: 514/159-164
• US Class Current: 514/159
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Abstract

For better control of pain, fever, inflammation and platelet aggregation in the human blood system, a tablet containing a relatively smaller amount of aspirin capable of rapid dissolution or disintegration in the oral, preferably sublingual, cavity permitting rapid absorption of the aspirin from the saliva into the blood system, and method of using such tablet.

Claims

1. A method of inhibiting platelet aggregation in the blood system of a human who has a need for such inhibition comprising administering to, and letting dissolve in, the oral cavity of said human a tablet which disintegrates in human saliva in less than about 60 seconds containing about 30 to about 190 mg. of aspirin.

2. A method according to claim 1 wherein said tablet contains about 50 to about 145 mg. of aspirin.

3. A method according to claim 1 wherein said tablet contains about 70 to about 90 mg. of aspirin.

4. A method according to claim 3 wherein said tablet further contains glycine.

5. A method according to claim 3 wherein said tablet further contains glycine in a glycine:

aspirin weight ratio of about 2.5;

1 to about 8;

1.

6. A method according to claim 1 wherein said tablet further contains glycine.

7. A method according to claim 1 wherein said tablet further containing glycine in a glycine:

aspirin weight ratio of about 2.5;

1 to about 8;

1.

8. A method according to claim 1 wherein said tablet so disintegrates in about 3 to about 15 seconds.

9. A method according to claim 8 wherein said tablet contains about 70 to about 90 mg. of aspirin.

10. A method according to claim 9 wherein said tablet further contains glycine in a glycine:

aspirin weight ratio of about 2.5;

1 to about 8;

1.

11. A method of inhibiting platelet aggregation in the blood system of a human who has a need for such inhibition comprising administering to, and letting dissolve in, the sublingual oral cavity of said human a tablet which disintegrates in human saliva in less than about 60 seconds containing about 30 to about 190 mg. of aspirin.

12. A method according to claim 11 wherein said tablet contains about 50 to about 145 mg. of aspirin.

13. A method according to claim 11 wherein said tablet contains about 70 to about 90 mg. of aspirin.

14. A method according to claim 13 wherein said tablet further contains glycine.

15. A method according to claim 13 wherein said tablet further contains glycine in a glycine:

aspirin weight ratio of about 2.5;

1 to about 8;

1.

16. A method according to claim 11 wherein said tablet further contains glycine.

17. A method according to claim 11 wherein said tablet further contains glycine in a glycine:

aspirin weight ratio of about 2.5;

1 to about 8;

1.

18. A method according to claim 11 wherein said tablet so disintegrates in about 3 to about 15 seconds.

19. A method according to claim 18 wherein said tablet contains about 70 to about 90 mg. of aspirin.

20. A method according to claim 19 wherein said tablet further contains glycine in a glycine:

aspirin weight ratio of about 2.5;

1 to about 8;

1.